Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nuvation BioNUVB +1.97%32 Gross Margin % is 70.11% as of Jun. 2026, which is 47% above its 10-year median of 47.66. GuruFocus rates NUVB with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 735 Biotechnology companies, Nuvation Bio ranks better than 81.36% on this metric.
Nuvation Bio (NYSE:NUVB) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Nuvation Bio had a gross margin of 70.11% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Nuvation Bio Gross Margin % Related Terms
Nuvation Bio Gross Margin % Historical Data
* Premium members only.
The historical data trend for Nuvation Bio's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NUVB vs IOVA, SLS, COAG: Gross Margin % Comparison
For the Biotechnology subindustry, Nuvation Bio's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuvation Bio Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuvation Bio's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Nuvation Bio's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Nuvation Bio (NUVB) has a Gross Margin % of 70.11% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Nuvation Bio and its competitors. This is 47% above median its historical median of 47.66. Over the past decade, Nuvation Bio's Gross Margin % has ranged from 10.10 to 88.18. According to the industry distribution chart, Nuvation Bio ranks #137 out of 735 companies in the Biotechnology industry, placing it in the top 18.6%.
Is Nuvation Bio's Gross Margin % too high?
Nuvation Bio's current Gross Margin % of 70.11% is 47% above median its 10-year median of 47.66. Over the past 10 years, this metric has ranged from a low of 10.10 to a high of 88.18. The Biotechnology industry median Gross Margin % is 60.91. Nuvation Bio's value of 70.11% is 15.1% above this industry median. Based on the distribution chart, Nuvation Bio ranks #137 out of 735 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Nuvation Bio has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Nuvation Bio's Gross Margin % compare to IOVA and SLS?
According to the Biotechnology industry distribution chart, Nuvation Bio ranks #137 out of 735 companies for Gross Margin %. This places Nuvation Bio in the top 19% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. Nuvation Bio's value of 70.11% is 15.1% above this benchmark. Historically, Nuvation Bio's own Gross Margin % has ranged from 10.10 to 88.18 over the past decade. While the company's 10-year median is 47.66 vs. the industry median of 60.91, Nuvation Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nuvation Bio's current Gross Margin % of 70.11% is 15.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Nuvation Bio and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nuvation Bio's current Gross Margin % is 70.11%, which is 47% above median its own 10-year median of 47.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuvation Bio stock overvalued right now?
Nuvation Bio (NUVB) has a current Gross Margin % of 70.11%. The current Gross Margin % is 70.11%, which is 47% above median its 10-year median of 47.66 and 15.1% above the Biotechnology industry median of 60.91. Nuvation Bio's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Nuvation Bio (NUVB), the current Gross Margin % is 70.11% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
32GF Score
Get the complete analysis for NUVB
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NUVB has been successfully added to your 
